388610.KQ GFC Life Science Co., Ltd
- Market cap
- KRW 22.7B
- P/E
- 22.0x
- P/B
- 0.91x
- ROE
- 7.2%
- Dividend yield
- -
- Fundamental score
- 2.0/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 388610.KQ undervalued?
Graham number388610.KQ trades 5.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GFC Life Science Co., Ltd fundamental analysis
10 of 22 checks passedROE 0/2
Low return on equity (7.2%), below 10%.
ROA 1/1
Return on assets (4.8%) is above the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (107.8%) is above the industry median (4.8%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (36.9%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 7.1x against interest expense, well covered.
PE vs Market 0/1
PE (22.0x) is above the market median (11.3x).
PE vs Industry 1/1
PE (22.0x) is below the industry median (28.9x).
PBV 1/1
Price to book (0.9x) is below the industry median (2.4x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 20.0, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
GFC Life Science Co., Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GFC Life Science Co., Ltd
GFC Life Science Co., Ltd develops cosmetic, food, and medical materials. The company develops bio-materials in the areas of human bio-technology, bio-phytochemistry, bio-fermentation, unique bio-technology, and biocompatible formula technology. It also offers scientific and systematic research services on human application testing. The company was formerly known as GFC Co., Ltd and changed its name to GFC Life Science Co., Ltd in 2018. GFC Life Science Co., Ltd was founded …
Full company profileGFC Life Science Co., Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GFC Life Science Co., Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 15.4B | 16.8B | 17.7B | 21.0B |
| Gross Profit | 6.81B | 7.88B | 8.51B | 11.3B |
| Operating Income | 704M | 1.70B | 386M | 2.09B |
| EBITDA | 5.21B | -2.66B | 2.11B | 4.38B |
| Net Income | 2.10B | -5.95B | 555M | 1.79B |
| EPS | 685 | -1,355 | 106 | 338 |
| Balance Sheet | ||||
| Total Assets | 18.8B | 20.1B | 33.8B | 37.4B |
| Total Liabilities | 20.0B | 9.16B | 10.0B | 12.5B |
| Shareholders' Equity | -1.16B | 10.9B | 23.8B | 24.9B |
| Cash & Short-term Investments | 1.48B | 1.54B | 7.47B | 6.57B |
| Cash Flow | ||||
| Operating Cash Flow | 2.27B | 2.97B | 1.37B | 2.52B |
| Capital Expenditure | 676M | 3.01B | 7.71B | 9.37B |
| Free Cash Flow | 1.59B | -43.8M | -6.34B | -6.85B |
| Ratios | ||||
| ROE | - | -54.6% | 2.3% | 7.2% |
| ROA | 11.2% | -29.7% | 1.6% | 4.8% |
| Net Profit Margin | 13.6% | -35.4% | 3.1% | 8.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GFC Life Science Co., Ltd dividends
GFC Life Science Co., Ltd has not paid dividends in the last 3 fiscal years.
Last stock split: 3:1 on Jul 24, 2023.
Who owns GFC Life Science Co., Ltd
- Insiders 36.27%
- Institutions 10.06%
- Public & others 53.68%
- Shares outstanding 5.31M
- Free float 3.30M
GFC Life Science Co., Ltd company profile
- Company name
- GFC Life Science Co., Ltd
- Ticker
- 388610.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 823, Dongtansunhwan-daero, Hwaseong-si, South Korea, 18471
- Phone
- 82 3 1518 3555
- Website
- gfcos.co.kr
About GFC Life Science Co., Ltd
GFC Life Science Co., Ltd develops cosmetic, food, and medical materials. The company develops bio-materials in the areas of human bio-technology, bio-phytochemistry, bio-fermentation, unique bio-technology, and biocompatible formula technology. It also offers scientific and systematic research services on human application testing. The company was formerly known as GFC Co., Ltd and changed its name to GFC Life Science Co., Ltd in 2018. GFC Life Science Co., Ltd was founded in 2002 and is headquartered in Hwaseong-si, South Korea.